Eruptive Xanthomas [0.03%]
爆发性黄瘤病
Ke-Yun Tang,Meng-Yin Wu,Jun Li
Ke-Yun Tang
Shared Decision-making, Therapeutic Choice and Decisional Regret in Alopecia Areata-Where Narrative Ethics Meets the Unconscious Bias of Clinicians-Reply [0.03%]
决策共享、治疗选择和脱发的决定性遗憾-叙事伦理与临床医生无意识偏见的交汇处-回复
Kathie Huang,Arash Mostaghimi
Kathie Huang
Treatment of Porokeratosis Ptychotropica With a Topical Combination of Cholesterol and Simvastatin [0.03%]
胆固醇和辛伐他汀联合治疗皮肤皱褶部位的派克erosis病灶
Marta Albanell-Fernández,Mar Luque-Luna,Carmen López-Cabezas et al.
Marta Albanell-Fernández et al.
Trends in the Prevalence of Eczema Among US Children by Age, Sex, Race, and Ethnicity From 1997 to 2018 [0.03%]
1997至2018年美国儿童湿疹患病率的年龄、性别、种族和 ethnicity分布趋势
Siri Choragudi,Gil Yosipovitch
Siri Choragudi
Shared Decision-making, Therapeutic Choice, and Decisional Regret in Alopecia Areata-Where Narrative Ethics Meets the Unconscious Bias of Clinicians [0.03%]
斑秃的共同决策、治疗选择与决定性遗憾——叙事伦理学与临床医生无意识偏见的碰撞
Leila Asfour,Bhaskar Narayan
Leila Asfour
Incorporating Social Determinants of Health Into Medical Decision-making-Implications for Dermatology [0.03%]
社会决定因素对医学决策的影响——皮肤科的启示
Kaushik P Venkatesh,Balaji Jothishankar,Vinod E Nambudiri
Kaushik P Venkatesh
Numerous Ulcerated Plaques of the Trunk and Extremities in a Patient Receiving Long-term Hydroxyurea Therapy [0.03%]
长期羟基脲治疗患者的躯干和四肢多发溃疡性斑块病变
Paul Wirth,Todd V Cartee,Charlene Lam
Paul Wirth
Surgical Procedural Definitions for Hidradenitis Suppurativa Developed by Expert Delphi Consensus [0.03%]
专家共识Delphi意见：形成汗腺炎手术操作定义标准
Helen Bui,Falk G Bechara,Ralph George et al.
Helen Bui et al.
Importance: Various surgical approaches for hidradenitis suppurativa (HS) have been described in the literature, but the nomenclature is inconsistent. Excisions have been described as wide, local, radical, and regional wi...
Mya L Roberson,Kanade Shinkai
Mya L Roberson
Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels [0.03%]
利妥昔单抗治疗系统性硬化症患者的长期疗效：DESIRES试验的随访研究，重点为血清免疫球蛋白水平
Ai Kuzumi,Satoshi Ebata,Takemichi Fukasawa et al.
Ai Kuzumi et al.
Importance: Rituximab is emerging as a promising therapeutic option for systemic sclerosis (SSc), but its long-term outcomes and response markers are unknown. ...
Clinical Trial
JAMA dermatology. 2023 Apr 1;159(4):374-383. DOI:10.1001/jamadermatol.2022.6340 2023